Navigation Links
Scripps Research scientists share $2 million in Florida state research grants
Date:6/30/2010

a collaborative research program in cancer therapy with William Roush, who is a professor in the Department of Chemistry, executive director of the Translational Research Institute Medical Chemistry Division, and associate dean of the Kellogg School of Science and Technology, and John Cleveland, chair of the Department of Cancer Biology.

"Cancer cells differ from most healthy cells in using one pathway, called glycolysis, to acquire nearly all of their energy from glucose, " Bannister said. "The pathway makes lactic acid, a byproduct they must pump out in order to survive. Our research is aimed at improving molecules we have discovered that block lactic acid export and acidify the tumor cells. Cancer cells also recognize our compounds as an amino acid that they need in abundance. This tricks tumor cells into taking in something that will kill them."

The major focus of Kojetin's work is to understand how the structural dynamics of proteins contribute to their biological function. Modulation of a protein's dynamic shape or conformation represents an avenue for drug discovery.

"For this grant, we're looking at nuclear receptor transcription factor proteins, which are receptors for small molecules and important drug discovery targets for a variety of human diseases, including cancer and type II diabetes," he said. "When compounds bind to these receptors, other proteins called transcriptional co-regulator proteins also bind, all of which helps regulate expression of target genes. Hopefully, our work will help in the development of drugs targeting a specific receptor we've identified as promising."


'/>"/>

Contact: Keith McKeown
kmckeown@scripps.edu
858-784-8134
Scripps Research Institute
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Scripps Announces Plans for Region's First Proton Therapy Center; $185 Million Facility to Offer Advanced Care to Cancer Patients
2. Scripps Memorial Hospital La Jolla First in San Diego to Achieve Magnet Nursing Re-designation
3. Scripps Blood & Marrow Transplant Program Celebrates 30th Anniversary of Providing Life-Saving Care
4. Top Scientists Explore the Origin of Life in Annual Lasker Lecture at Scripps Research Institute Florida Campus
5. Scripps Health Begins Pioneering Study of Human Tumor Sequencing in Cancer Patients
6. Fitch, Standard & Poor's Upgrade Scripps Health to AA-; Scripps to Issue $220 Million in Hospital Revenue Bonds
7. Scripps Health Preparing for Deployment of Medical Response Team to Haiti
8. Scripps Research scientists find cancer cells co-opt fat metabolism pathway to become more malignant
9. New Chief of Staff Takes Over at Scripps Memorial Hospital La Jolla
10. Scripps Research scientists reveal key structure from ebola virus
11. Psychological research conducted in WEIRD nations may not apply to global populations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... ... ... “would be” entrepreneurs, starting a new business can prove to be daunting from the viewpoint ... needs be a major obstacle. , The U.S. has always been the land of ... The risks of starting a business can be high but the rewards can be well ...
(Date:8/1/2015)... ... , ... Back packs can be dangerous? Whaaat?! , Not the danger that ... on a kid's spine. With school starting again, most kids will be asking for ... are aware of how to help them prevent injuries by understanding backpack safety. , ...
(Date:8/1/2015)... NY (PRWEB) , ... August 01, 2015 , ... Calvary ... scroll currently housed at their Bronx campus. The goal is to bring this Torah ... again be used in Jewish rituals and religious services. , Scroll No. 515, ...
(Date:8/1/2015)... York, NY (PRWEB) , ... August 01, 2015 , ... ... Vine cyberespionage group , who are thought to have been behind the attack on ... the topics covered were zero day exploits, watering hole attacks and spear phishing campaigns. ...
(Date:8/1/2015)... ... 2015 , ... On March 19, 2015 Phil Valentine – the Executive Director of Connecticut Community ... by stepping off Springer Mountain and heading north. Since that day, Phil has hiked ... and was greeted by friends and family. He visited CCAR and left an inspirational ...
Breaking Medicine News(10 mins):Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2
... Institute researcher Jeff Tyner, Ph.D., has created a way to ... myeloid leukemia using an assay that yields results in just ... Society of Hematology annual meeting in Atlanta, on Monday, Dec. ... assay, called RAPID, because it rapidly delivers the information, has ...
... DIEGO, Dec. 10 ADVENTRX Pharmaceuticals,Inc. (Amex: ... on commercializing proprietary product candidates for the treatment,of ... M. Culley,ADVENTRX,s chief business officer, is scheduled to ... as part of a panel on Better Drugs ...
... Human Resources Professional Brings Diverse Expertise, MIAMI, ... biotherapeutic products to healthcare providers, is pleased,to announce ... Vice President of,Human Resources. Ms. Lopez was most ... & Johnson Company. Her 17-year career began,in Human ...
... States may be less likely to report a family history ... prevention strategies according to a new study. Dr. Heather Orom ... colleagues argue that as a result of being less likely ... as strong a predictor of cancer risk in immigrant populations. ...
... and post-stem cell transplantation results compared to thalidomide and ... ... Pharmaceuticals,Inc. (Nasdaq: MLNM ) reported the presentation of results from ... randomized,Phase III clinical trial. This study compared VELCADE, thalidomide and,dexamethasone (VcTD) ...
... improvement across all ... survival -, ATLANTA, Dec. 9 Millennium Pharmaceuticals,Inc. ... results from the,682 patient, randomized, Phase III VISTA(1) trial. ... for stem cell,transplantation (SCT). The trial compared VELCADE, melphalan ...
Cached Medicine News:Health News:OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia 2Health News:ADVENTRX Pharmaceuticals to Present at the 2007 RBC Capital Markets Healthcare Conference 2Health News:Novis Pharmaceuticals Hires Lisa Lopez 2Health News:Immigrant patients less likely to report family history of cancer 2Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 2Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 3Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 4Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 5Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 6Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 2Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 3Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 4Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 5Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 6Health News:Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy 7
(Date:8/2/2015)... Aug. 3, 2015  Lexicon Pharmaceuticals, Inc. (Nasdaq: ... TELESTAR Phase 3 clinical trial met its primary ... in treating cancer patients with carcinoid syndrome that ... of care. Telotristat etiprate was discovered using Lexicon,s ... is the company,s first discovery to complete a ...
(Date:7/31/2015)... 31, 2015 Today, the National Association ... ) issued a report urging greater accountability by ... taken against websites illegally selling medications online. As ... Identification Program Progress Report for State and Federal ... of websites illegally distribute medications and avoid retribution. ...
(Date:7/31/2015)... TAMPA, Fla. , July 31, 2015 /PRNewswire/ ... announced today that it has made a structured ... -based company specializing in milling, micronization and ... investment will help grow Powdersize,s business while simultaneously ... solutions to Xcelience,s portfolio of capabilities. ...
Breaking Medicine Technology:Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 3Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3
... Perrigo Company (Nasdaq: PRGO ; TASE) and its ... tentative approval from the U.S. Food and Drug Administration for ... a generic version of UCB,s Xyzal® Oral Solution. Synthon believes ... generic that can entitle it to 180 days of generic ...
... -- Concord Medical Services Holdings Limited ("Concord Medical" ... of the largest network of radiotherapy and diagnostic imaging centers ... the first quarter ended March 31, 2011 (1). ... Total net revenues in the first quarter of 2011 ...
Cached Medicine Technology:Perrigo's Partner Synthon Receives FDA Tentative Approval for Levocetirizine Solution - Generic Equivalent to Xyzal® Oral Solution 2Perrigo's Partner Synthon Receives FDA Tentative Approval for Levocetirizine Solution - Generic Equivalent to Xyzal® Oral Solution 3Concord Medical Announces First Quarter 2011 Financial Results 2Concord Medical Announces First Quarter 2011 Financial Results 3Concord Medical Announces First Quarter 2011 Financial Results 4Concord Medical Announces First Quarter 2011 Financial Results 5Concord Medical Announces First Quarter 2011 Financial Results 6Concord Medical Announces First Quarter 2011 Financial Results 7Concord Medical Announces First Quarter 2011 Financial Results 8Concord Medical Announces First Quarter 2011 Financial Results 9Concord Medical Announces First Quarter 2011 Financial Results 10Concord Medical Announces First Quarter 2011 Financial Results 11Concord Medical Announces First Quarter 2011 Financial Results 12Concord Medical Announces First Quarter 2011 Financial Results 13
... Pars Plana glaucoma implant is the first ... or following a pars plana vitrectomy. The ... through a 20 gauge pars plana sclerostemy ... design accomplishment, combining the largest surface area ...
... automatic or manual kinetic and static ... or red/white stimuli/background colors. Static perimetry ... threshold strategy. Examination with pre-programmed or ... 24-2, and 10-2). Gray-scale/ Scotoma curve, ...
... lightweight enough to shuttle easily between offices ... with a goldmann standard 30 cm radius ... 79 locations (including 30-2, 24-2, and 10-2) ... suprathresholds out to 30. Easyfield is ...
The Oculus easyfield is an exciting new compact perimeter to do automatic static perimetry up to 30 degrees eccentricity. It has been designed for the combined use as a visual field screener and peri...
Medicine Products: